Clinical trials: Dry Eye Disease (DED)
Dry Eye Disease (DED)
Immediate Therapeutic Effects of Diquafosol and Rebamipide in Dry Eye Disease
This study compares the immediate therapeutic and mucin-secreting effects 30 minutes after instillation of 3% diquafosol and 2% rebamipide in dry eye disease.
- Trial name
- NCT07297316
- Testing
- 3% diquafosol (right eye) and 2% rebamipide (left eye), 2% rebamipide (right eye) and 3% diquafosol (left eye)
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Korea University Anam Hospital
Dry Eye Disease
Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.
To assess the safety, tolerability and efficacy of a single dose of OTX-CSI, a sustained release cyclosporine drug product, in subjects with dry eye disease.
- Trial name
- NCT04362670
- Testing
- OTX-CSI
- Where
- 15 sites in United States
- Volunteers
- 153 people
- Sponsor
- Ocular Therapeutix, Inc.
Dry Eye Disease (DED)
Comparative Effects of Autologous Serum, Umbilical Cord Blood-Derived Drops, and Platelet Lysate on Ocular Surface Parameters
In this study, patients are randomly assigned to the study groups (autologous peripheral blood, umbilical cord blood, autologous serum).
- Trial name
- DED (NCT07551843)
- Testing
- Autologous serum eyedrops, Autologous Platelet Lysate, Umbilical Cord Blood Platelet Lysate
- Where
- Greece
- Volunteers
- 80 people
- Sponsor
- G.Gennimatas General Hospital
Dry Eye Disease (DED)
New Preservative-free Combination of Trehalose, Sodium Hyaluronate and N-acetyl-aspartyl-glutamate (NAAGA) in Dry Eye
The goal of this prospective, non-randomized, non-comparative, monocentric PMCF study is to assess the performance of a new preservative-free combination of trehalose, sodium hyaluronate and NAAGA on DED at 6 months in 30…
- Trial name
- NCT06903741
- Testing
- T2769
- Where
- Bulgaria
- Volunteers
- 30 people
- Sponsor
- Laboratoires Thea
Dry Eye Disease (DED)
Vizol S DIGI EYE Efficacy and Safety Study in Patients With Dry Eye
The clinical investigation was intended to investigate the efficacy, ocular tolerability and safety of Vizol S DIGI EYE, a new eye drops, solution developed by JADRAN - GALENSKI LABORATORIJ d.d., in patients with moderate to…
- Trial name
- NCT07050446
- Testing
- Vizol S DIGI EYE eye drops, 0,9% saline solution, eye drops
- Where
- 3 sites in Serbia
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Jadran Galenski laboratorij d.d.
Dry Eye Disease (DED), Cataract Surgery
POST CATARACT SURGERY DRY EYE DISEASE
Cataract surgery is one of the most frequent and successful interventions currently undertaken in medicine. However, a significant number of patients who underwent cataract surgery still complain about postoperative symptoms…
- Trial name
- NCT07715266
- Testing
- NOX-01
- Where
- 2 sites in Spain
- Volunteers
- 33 people
- Sponsor
- NOXELIS
Dry Eye Disease (DED), Dry Eye
Proteomics Analysis of Human Tears in the Diagnosis and Management of Dry Eye Disease
In this study, the initial tear proteome profiles in Dry Eye Disease (DED) patients, the safety and effectiveness of using an EC certificate DED treatment device in DED management, together with the associated global tear…
- Trial name
- NCT07175909
- Testing
- The Rexon-Eye, an electrotherapy device utilizing Quantum Molecular Resonance (QMR) technology
- Where
- Hong Kong
- Volunteers
- 75 people
- Sponsor
- The Hong Kong Polytechnic University
Dry Eye Disease (DED)
The Effect of 0.1% Topical Ciclosporin A for 12-weeks on the Eye Surface Immune Cells in Dry Eyes
Dry eye disease (DED) is a common, long-lasting condition that affects the surface of the eye. It happens when there's a problem with tear production or quality, which can lead to inflammation and discomfort.
- Trial name
- NCT06898853
- Testing
- 0.1% Ciclosporin A eye drops, Mineral oils eye drops
- Where
- Australia
- Volunteers
- 60 people
- Sponsor
- The University of New South Wales
Dry Eye Disease (DED)
The Effectiveness of Systane PRO Preservative Free Verses Blink Triple Care Preservative Free
The goal of this investigational study is to determine if Systane PRO Preservative Free is non-inferior to BLINK TRIPLE CARE in the clinically significant improvement of signs and symptoms of dry eye in patients over 4 weeks.
- Trial name
- SYSTANEvBLINK (NCT07745062)
- Testing
- Systane PRO, Blink tears
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Gordon Schanzlin New Vision
Evaporative Dry Eye Disease
Evaluation of MAF-1217 in Patients With DED
This is a pre-market, multicentre, double-blind, randomized, crossover, non-inferiority study comparing the efficacy of MAF-1217 and Cationorm® in adult patients with evaporative DED.
- Trial name
- NCT03833882
- Testing
- MAF1217, Cationorm
- Where
- 2 sites in Italy
- Volunteers
- 72 people
- Sponsor
- VISUfarma SpA
Dry Eye Disease (DED), Asthenopia
Effect of Smart Phone Reflective Light Film on Dry Eyes and Asthenopia
This study aimed to evaluate the effect of anti-reflection (AR) and circularly polarized (CP) film on video display terminal (VDT) induced dry eye and asthenopia after limited time and close distance of visual tasks under light…
- Trial name
- NCT06992635
- Testing
- using non-processing screens, using AR+CP screens
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Dry Eye Disease, Endothelial Cell
A Clinical Trial to Evaluate the Corneal Endothelial Health of DED Subjects Treated With Cyclosporine
The objective of this trial is to evaluate the effect of cyclosporine ophthalmic solution, 0.1% on corneal endothelial cell health in comparison to a hypotonic saline solution in subjects with Dry Eye Disease (DED)
- Trial name
- NCT06329661
- Testing
- Cyclosporine ophthalmic solution, 0.1%, Saline solution, 0.6%
- Where
- 6 sites in United States
- Volunteers
- 204 people
- Sponsor
- Novaliq GmbH
Dry Eye Disease
HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED)
The purpose of this study is to determine whether SYL1001 ophthalmic solution is safe and effective in the treatment of signs and symptoms of Dry Eye Disease.
- Trial name
- NCT03108664
- Testing
- SYL1001 ophthalmic solution, Vehicle opthalmic solution
- Where
- 40 sites in Estonia, Germany and 4 more
- Volunteers
- 330 people
- Sponsor
- Sylentis, S.A.
Dry Eye Disease (DED)
Randomized Single Center Study to Evaluate Tolerability, Symptoms, and Visual Functional Outcomes With the Use of OTC Lubricating Eye Drops in Subjects With Dry Eye Disease
A study to evaluate the effect of over- the- counter (OTC) lubricating eye drops on tolerability, symptoms and visual outcomes in patients with dry eye disease (DED)
- Trial name
- NCT07676084
- Testing
- Preservative Free Polyethylene glycol 400 0.25%, Propylene Glycol (0.6%), Carboxymethylcellulose sodium 0.5%, Glycerin 1.0%, Polysorbate 80 0.5%
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Andover Research Eye Institute
Dry Eye Disease (DED)
Clinical Efficacy and Molecular Dynamics of Quantum Molecular Resonance (QMR) Electrotherapy in Dry Eye Management
This project aims to investigate the clinical efficacy and molecular mechanisms of Quantum Molecular Resonance (QMR) electrotherapy in the management of dry eye disease (DED).
- Trial name
- NCT06955806
- Testing
- The Rexon-Eye, an electrotherapy device utilizing Quantum Molecular Resonance (QMR) technology
- Where
- Hong Kong
- Volunteers
- 30 people
- Sponsor
- The Hong Kong Polytechnic University
Dry Eye Disease
A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.
Primary objective To evaluate the efficacy of 5 μg/mL and 10 μg/mL concentrations of the new formulation of rhNGF ophthalmic solution versus vehicle, in order to demonstrate superiority of at least 1 of the concentrations over…
- Trial name
- REDUCO (NCT06244316)
- Testing
- rhNGF 5 μg/mL, rhNGF 10 μg/mL
- Where
- 14 sites in United States, Italy
- Volunteers
- 317 people
- Sponsor
- Dompé Farmaceutici S.p.A
Dry Eye Disease
Safety and Efficacy of ST-100 (Vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution in Subjects Diagnosed With Dry Eye Disease (DED)
A Phase 3 Multi-Center, Randomized, Double Masked, Vehicle Controlled Study to Assess the Safety and Efficacy of ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution in Subjects Diagnosed with Dry Eye Disease…
- Trial name
- NCT06178679
- Testing
- ST-100 (vezocolmitide), Vehicle
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- ORA, Inc.
Dry Eye Disease (DED) , Diabetic Macular Edema
Association Between Dry Eye Disease and Diabetic Macular Edema
This study evaluates the association between dry eye disease (DED) and diabetic macular edema (DME) in adult patients at the Ophthalmology Department, Faculty of Medicine, Sohag University.
- Trial name
- DED-DME (NCT07392307)
- Testing
- Dry Eye Disease Assessment
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University
Dry Eye Disease (DED), Asthenopia
Tear Film Stability and Improvement of Asthenopia: Efficacy Observation of 0.05% Cyclosporine in Dry Eye Patients With Short BUT
At present, research on cyclosporine mainly focuses on patients with moderate to severe dry eye. Based on the importance of the vicious cycle of inflammation in the pathogenesis of dry eye and the mechanism of cyclosporine…
- Trial name
- NCT06981104
- Testing
- 0.05% cyclosporine eyedrops, 0.1% sodium hyaluronate eye drop
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Dry Eye Disease (DED)
Efficacy of Pilocarpine As a Secretagogue Versus Artificial Tears for the Treatment of Dry Eye
Management approaches for dry eye disease (DED) typically start with low-risk, easily accessible, patient-applied therapies like artificial tears for early-stage disease.
- Trial name
- NCT06752278
- Testing
- Pilocarpine, artificial tears
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Al-Azhar University